{'fraction_non_alphanumeric': 0.030660377358490566, 'fraction_numerical': 0.02122641509433962, 'mean_word_length': 5.004716981132075, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Growth dependency of a new human pancreatic cancer cell line, YAPC, on autocrine interleukin‐1α stimulation

We established a new human pancreatic cancer cell line from the malignant ascites of a patient with pancreatic cancer and called it YAPC. Cytogenetic and morphological analysis indicated that this cell line is monoclonal and of human origin. YAPC cells grow in nude mice, resulting in the formation of a tumor with some functional characteristics of the original tumor. The cells secreted a large amount of inflammatory cytokines including interleukin‐1α (IL‐1α), IL‐6 and IL‐8 in the culture medium. Removal of serum from the culture medium did not change the growth rate of YAPC cells, but the removal of the conditioned medium arrested their proliferation under the serum‐free conditions. Exogenous IL‐1α but neither IL‐6 nor IL‐8 stimulated DNA synthesis of the cells and accelerated the progress of cell cycle from G1 to the S phase. Anti‐IL‐1α antibody prevented growth of the cells in a dose‐dependent fashion. In this pancreatic cancer cell line cell growth is dependent on IL‐1α in an autocrine fashion. This line may be a useful model for studying growth regulation mechanisms of pancreatic cancer. Int. J. Cancer76:141–147, 1998.© 1998 Wiley‐Liss, Inc.